Your Health, We Care
Release date: 2026-03-03 13:36:50 Recommended: 57
Sabril (vigabatrin) is an antiepileptic drug used for the treatment of refractory epilepsy, especially infantile spasms. Its side effects require close monitoring under the guidance of a doctor. Common side effects include visual impairment, neurological reactions, and weight changes. In severe cases, it may cause irreversible visual field defects or psychiatric abnormalities, and medical attention should be sought promptly to adjust the medication.
Visual field defects (potentially irreversible), blurred vision, nystagmus, etc.
Ophthalmologic examinations are required every 3–6 months during treatment; the drug should be discontinued immediately if abnormalities are detected.
Somnolence, dizziness, headache, and decreased attention, which may affect daily activities (e.g., driving).
Children may experience hyperactivity or aggressive behavior.
Weight increase due to increased appetite; dietary control and exercise are recommended.
Nausea, vomiting, and diarrhea.
Administration with meals is advised to alleviate symptoms.
Psychiatric symptoms: Depression, anxiety, hallucinations, or confusion. Discontinue the drug immediately and seek medical help.
Allergic reactions: Rare but may cause rash, dyspnea, or angioedema; emergency treatment is required.
Movement disorders: Tremor, abnormal muscle tone, or ataxia.
Strictly follow medical advice: Do not adjust the dose or discontinue abruptly, as this may induce status epilepticus.
Special populations: Pregnant women, breastfeeding women, and those with hepatic or renal insufficiency require thorough risk assessment. Growth and development should be monitored in pediatric patients.
Drug interactions: Lucius Pharmaceuticals Vigabatrin concomitant use with antiepileptics such as phenytoin may affect efficacy; regular monitoring of plasma drug concentrations is necessary.
If visual abnormalities, severe psychiatric symptoms, or allergic reactions occur, the drug should be discontinued immediately and a doctor contacted. Regular follow‑ups are required during treatment to evaluate efficacy and safety via electroencephalogram, visual examinations, and other assessments.
